Serina Therapeutics
SER
52 hedge funds and large institutions have $18.7M invested in Serina Therapeutics in 2018 Q4 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.49% more ownership
Funds ownership: 0% → 0.49% (+0.49%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$10.8M |
| 2 |
BlackRock
New York
|
+$2.19M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.71M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$1.71M |
| 5 |
State Street
Boston,
Massachusetts
|
+$845K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
51
TCI Wealth Advisors
Tucson,
Arizona
| – | +$509 | +4 | New |
|
52
Barclays
London,
United Kingdom
| – | +$890 | +7 | New |
|
SER Hedge Fund Activity: Q4 2018 in Review
52 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q4 2018, worth a combined $18.7M.
Buyers outnumbered sellers: 52 funds opened new SER positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadwood Capital, opening a new position worth an estimated $10.8M.
- 52 institutional investors held Serina Therapeutics (SER) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $18.7M of Serina Therapeutics stock for Q4 2018.
- 52 funds opened new Serina Therapeutics positions in Q4 2018 and 0 closed out, a net change of +52 holders.
- The largest Serina Therapeutics buyer in Q4 2018 was Broadwood Capital, an estimated $10.8M added.
Based on aggregated 13F filings for Q4 2018.